{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:49:21Z","timestamp":1786373361816,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.2215\/cjn.11340922","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T11:30:15Z","timestamp":1666870215000},"page":"1583-1585","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The Role of Anti-B Cell Activating Factor Therapy for Treating Lupus Nephritis"],"prefix":"10.2215","volume":"17","author":[{"given":"Benjamin","family":"Wooden","sequence":"first","affiliation":[{"name":"Division of Nephrology, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Radhakrishnan","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: Results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11926-012-0258-2","article-title":"The rationale for BAFF inhibition in systemic lupus erythematosus","volume":"14","author":"Davidson","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.biocel.2009.10.011","article-title":"The role of B cells in lupus pathogenesis","volume":"42","author":"Nashi","year":"2010","journal-title":"Int J Biochem Cell Biol"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.coi.2012.10.004","article-title":"The pathogenesis of systemic lupus erythematosus-An update","volume":"24","author":"Choi","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B6-20241015","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases"},{"key":"B7-20241015","first-page":"CD002922","article-title":"Immunosuppressive treatment for proliferative lupus nephritis","volume":"6","author":"Tunnicliffe","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.02520322","article-title":"Safety and efficacy of belimumab in patients with lupus nephritis: Open-label extension of BLISS-LN study","volume":"17","author":"Furie R, Rovin BH, Houssiau F, Contreras G, Teng YKO, Curtis P, Green Y, Okily M, Madan A, Roth DA","year":"2022","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.11340922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:11Z","timestamp":1786369511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.11340922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.11340922","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}